Improving Phase I Dose-Finding Studies
Author Information
Author(s): O'quigley J, Zohar S
Primary Institution: Institut Curie, Paris, France
Hypothesis
New designs with memory are more efficient than traditional memoryless designs in phase I dose-finding studies.
Conclusion
Designs with memory can treat more patients at the maximum tolerated dose and require fewer patients overall compared to memoryless designs.
Supporting Evidence
- New designs with memory require fewer patients to find the maximum tolerated dose.
- Retrospective analyses show that designs with memory treat more patients at the maximum tolerated dose.
- The study highlights the inefficiencies of traditional memoryless designs in clinical trials.
Takeaway
This study shows that using smarter methods in drug trials can help doctors find the best dose for patients faster and with fewer mistakes.
Methodology
The study reviews and compares traditional memoryless designs with newer designs that incorporate memory, analyzing their effectiveness in clinical trials.
Potential Biases
Potential biases may arise from the reliance on historical data and assumptions in simulations.
Limitations
The study relies on retrospective analyses and simulations, which may not fully capture real-world complexities.
Participant Demographics
The trials included a total of 20 to 33 patients across various studies, with varying demographics based on the specific trials.
Statistical Information
Confidence Interval
(0.07, 0.39)
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website